NVP-BSK805,
NVP-BSK805,
1092499-93-8,
4-(2,6-difluoro-4-(3-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)quinoxalin-5-yl)benzyl)morpholine,
BSK 805,
8-[3,5-difluoro-4-(morpholin-4-ylmethyl)phenyl]-2-(1-piperidin-4-yl-1H-pyrazol-4-yl)quinoxaline,
BSK805,
CHEMBL1092926,
8-(3,5-difluoro-4-(morpholinomethyl)phenyl)-2-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)quinoxaline,
DQX,
8-(3,5-DIFLUORO-4-(MORPHOLINOMETHYL)PHENYL)-2-(1-(PIPERIDIN-4-YL)-1H-PYRAZOL-4-YL)QUINOXALINE DIHYDROCHLORIDE,
NVPBSK805,
NVP-BSK 805 HCl,
C27H30Cl2F2N6O,
NVP-BSK 805,
SCHEMBL2800994,
EX-A286,
IBPVXAOOVUAOKJ-UHFFFAOYSA-N,
BCP29570,
KS-00000M2J,
BDBM50315231,
ZINC49070412,
CS-1629,
NCGC00263202-01,
NCGC00263202-08,
AC-28460,
AK473881,
HY-14722,
X7514,
Q27459702,
NVP-BSK 805;NVPBSK805; NVP BSK805; BSK805; BSK 805;BSK-805,
8-(3,5-Difluoro-4-morpholin-4-ylmethyl-phenyl)-2-(1-piperidin-4-yl-1H-pyrazol-4-yl)-quinoxaline,
NVP-BSK805 2HCl,
NVP-BSK805 dihydrochloride,
A3675,
C553194,
8-[3,5-Difluoro-4-(4-morpholinylmethyl)phenyl]-2-[1-(4-piperidinyl)-1H-pyrazol-4-yl]quinoxaline HCl,